Company News
July 08 Imperial Innovations licence global rights for Tournistrip to ASep Healthcare.
Tournistrip, the only tourniquet to have been clinically trialed
78% of phlebotomists actually preferred Tournistrip to their current tourniquet
A high proportion of conventional tourniquets are contaminated with blood and bacterial pathogens
The average reusable Tourniquet is owned for 1.86 years
Tournistrip's unique design and construction mean that it is truly single use